Long acting GLP-1 receptor agonist (injectable)
Semaglutide 0.05 mg injection once daily
SEMA_SC_0p05MG_QD
Related
- All doses pooled: Semaglutide injection
- Semaglutide 1.0 mg subcutaneous once weekly
- Semaglutide maximum tolerated dose injection once weekly
- Semaglutide 2.4 mg subcutaneous once weekly
- Semaglutide 0.5 mg subcutaneous once weekly
- Semaglutide 0.5 mg injection
- Semaglutide flexible dose injection once weekly
- Semaglutide 0.4 mg injection once daily
- Semaglutide 0.1 mg injection once daily
- Semaglutide 0.2 mg injection once daily
- Semaglutide 0.25 mg injection
- Semaglutide 2.0 mg subcutaneous once weekly
- Semaglutide 1.5 mg injection once weekly
- Semaglutide 8 mg injection once weekly
- Semaglutide 16 mg injection once weekly
- Semaglutide 0.1072 mg injection
- Semaglutide 1.7 mg injection once weekly
- Semaglutide flexible dose injection once weekly
- Semaglutide 0.3 mg injection once daily
- Semaglutide flexible dose injection once weekly
- Semaglutide 2.4 mg injection
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Overweight or obesity without diabetes (adults) | Systolic blood pressure change | weeks 40 to 104 (target week 68) | Placebo | MD -2.99 (-7.70 to 1.46) | 0.37 |
| Overweight or obesity without diabetes (adults) | Percent body weight change | weeks 40 to 104 (target week 68) | Placebo | MD -3.56 (-7.06 to 0.01) | 0.18 |
| Overweight or obesity without diabetes (adults) | SF-36 physical component summary change | weeks 20 to 130 (target week 52) | Placebo | MD 0.49 (-3.32 to 4.55) | 0.33 |
| Overweight or obesity without diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 2.22 (0.88 to 5.50) | 0.29 |
| Overweight or obesity without diabetes (adults) | Nausea | longest follow-up | Placebo | HR 2.18 (1.32 to 3.55) | 0.74 |
| Overweight or obesity without diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 2.08 (0.81 to 5.14) | 0.74 |
| Overweight or obesity without diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 1.25 (0.62 to 2.53) | 0.69 |
| Overweight or obesity without diabetes (adults) | Constipation | longest follow-up | Placebo | HR 1.63 (0.68 to 3.85) | 0.59 |